Phase 2b Prostate Cancer Study Receives FDA Clearance in High-Risk Groups
The big picture: The Food and Drug Administration (FDA) has given clearance to a groundbreaking Phase 2b prostate cancer study for high-risk groups, a significant milestone in cancer research.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
A partial clinical hold has been issued by the FDA on the Lorigerlimab trial relating to gynecologic cancers, creating a potential hiatus in progress.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Management strategies for immune-checkpoint inhibitor toxicities are being refined in the field of melanoma treatment, improving therapeutic outcomes.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The highlight: The FDA has granted fast track designation to SRN-101, a potential new treatment for recurrent high-grade glioma, as part of their accelerated approval program.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Positive signs are evident, with a novel small molecule showing early activity in the treatment of multiple myeloma, presenting new hope for patient options.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
Recent research compares the quality of life outcomes with the use of protons versus photons in OPSCC treatment, highlighting complex decision challenges.
